CYP19A1 and breast carcinoma: In conclusion, this study revealed that patients weighted importance on PFS, anemia, and pneumonitis, when they needed to choose an aromatase inhibitor plus mTOR inhibitor for advanced breast cancer treatments after failure of standard treatments.